<DOC>
	<DOC>NCT01051206</DOC>
	<brief_summary>HES 130/0.4 significantly solution will not affect on coagulation and blood loss in patients medicated with antiplatelet agents prior to off-pump coronary bypass surgery (OPCAB).</brief_summary>
	<brief_title>The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery</brief_title>
	<detailed_description />
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>Eighty patients undergoing OPCAB, who were exposed to anti platelet agents until 5 days prior to surgery were randomly allocated to infuse HES 130/0.4 up to 30 ml/kg and followed crystalloid infusion or infuse crystalloid only during perioperative period, Patient who has Valvular disease of heart MI within 3 months,patient under 40% of left ventricle preoperative output left main artery stenosis anemia (hemoglobin &lt; 12 g/dl), coagulopathy (Platelet &lt; 100/nl, activated partial thromboplastin time, aPTT) &gt; 80sec, serum creatinine &gt; 1.2 mg/dl, respiratory disease(asthma, COPD, PaO2 &lt; 70 mmHg, pulmonary hypertension or pulmonary edema, etc) not consented to this trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>